Abstract:5577 Background: To evaluate the safety and efficacy of cetuximab combined with IMRT + concurrent cisplatin chemotherapy in patients with loco-regionally advanced NPC in a Chinese multicenter clinical study. Methods: Patients with primary stage III – IVb non- keratinizing NPC were enrolled. The planned dose of IMRT to gross tumor volume (GTV) was 66 - 75.9 Gy in 30-33 fractions. Cisplatin (80mg/m2,q3week [w]) and cetuximab (400mg/m2 one w before radiation, and then 250mg/m2/w) were given concurrently for 6 - 7 weeks. The response rate was evaluated according to RECIST, and adverse events (AEs) were graded according to CTCAE v3.0. Results: From July 2008 to April 2009, 100 patients were enrolled with 74 male and 26 female. Median age was 43 years old. The proportion of patients with stage III, IVa and IVb disease was 71%, 22% and 7%, respectively. Actual median dose to GTV was 69.96 Gy. Median dose of cisplatin was 133.17 mg, median first-dose of cetuximab was 690 mg, and median weekly dose was 410 mg. 99% of all included patients finished the planned treatment. AEs were well tolerated and manageable, mainly consisting of acneiform skin eruptions, dermatitis, mucositis, xerostomia and slight ALT elevations (grade 1 - 2). Only one patient had a mild allergic reaction, happening in the first w of cetuximab therapy. 64% of patients had ≥ grade 2 acneiform eruptions, mainly starting at the third week of cetuximab treatment. From the third week of radiotherapy, 58% and 90% of the patients began to suffer from grade 1 dermatitis and ≥ grade 2 mucositis, respectively, while grade 4 mucositis (spontaneous bleeding) was observed in 2% of the patients. 40% of patients experienced ≥ grade 2 xerostomia. Besides mucositis, no other grade 4 AEs were observed. Bone marrow suppression was mild, and only 8%, 4% and 5% patients had ≥ grade 2 decreased ANC, Plt and Hb, respectively. At the third month after treatment, 1 patient died of dysphagia. Clinical remission rate (CR + PR) was 100%. Conclusions: The combined treatment modality of IMRT + concurrent chemotherapy + cetuximab in loco- regionally advanced NPC was well tolerated, with a very encouraging clinical response rate. No significant financial relationships to disclose.

Combining Cetuximab with Chemoradiotherapy in Patients with Locally Advanced Nasopharyngeal Carcinoma: A Propensity Score Analysis.

Effectiveness of Cetuximab in Combination with Concurrent Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma: A 1:2 Propensity Score-matched Analysis.

Cetuximab in Combination with Chemoradiation after Induction Chemotherapy of Locoregionally Advanced Nasopharyngeal Carcinoma: Preliminary Results

Concurrent Chemoradiotherapy with or without Anti-EGFR-Targeted Treatment for Stage II-IVb Nasopharyngeal Carcinoma: Retrospective Analysis with a Large Cohort and Long Follow-up

Long-Term Result of A Multicenter Clinical Study of Cetuximab Combined with Intensity Modulated Radiotherapy (imrt) Plus Concurrent Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma (Npc).

Beneficial effects of anti-EGFR agents, Cetuximab or Nimotuzumab, in combination with concurrent chemoradiotherapy in advanced nasopharyngeal carcinoma.

An Open-Labeled, Multicentric Clinical Study of Cetuximab Combined with Intensity-Modulated Radiotherapy (IMRT) Plus Concurrent Chemotherapy in Locoregionally Advanced (LA) Nasopharyngeal Carcinoma (NPC): A 2-Year Follow-Up Report.

Cetuximab in Combination with Chemoradiotherapy in the Treatment of Recurrent And/or Metastatic Nasopharyngeal Carcinoma.

Cetuximab concurrent with IMRT versus cisplatin concurrent with IMRT in locally advanced nasopharyngeal carcinoma: A retrospective matched case-control study.

An Open, Multicenter Clinical Study on Cetuximab Combined with Intensity Modulated Radiotherapy (imrt) Plus Concurrent Chemotherapy in Nasopharyngeal Carcinoma (npc): Preliminary Report

Long-Term Survival of Patients with Chemotherapy-Naïve Metastatic Nasopharyngeal Carcinoma Receiving Cetuximab Plus Docetaxel and Cisplatin Regimen.

Weekly cetuximab concurrent with IMRT aggravated radiation-induced oral mucositis in locally advanced nasopharyngeal carcinoma: Results of a randomized phase II study

Survival Benefit Of Adding Chemotherapy To Intensity Modulated Radiation In Patients With Locoregionally Advanced Nasopharyngeal Carcinoma

Clinical Study of Cetuximab Combined with Radiotherapy and Chemotherapy for Treating Advanced Nasopharyngeal Carcinoma

Propensity Score Matching Analysis of Cisplatin-Based Concurrent Chemotherapy in Low Risk Nasopharyngeal Carcinoma in the Intensity-Modulated Radiotherapy Era

combination treatment with cetuximab in advanced nasopharyngeal carcinoma patients: a meta-analysis

Induction versus adjuvant chemotherapy combined with concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: A propensity score-matched analysis

Concurrent Chemoradiotherapy with Additional Chemotherapy for Nasopharyngeal Carcinoma: A Pooled Analysis of Propensity Score‐matching Studies

Prospective Study of Cetuximab with Cisplatin Plus Docetaxel Followed by Concurrent Radiotherapy Plus Cetuximab and Cisplatin in Patients with Chemotherapy-Naive Metastatic Nasopharyngeal Carcinoma

Palliative chemotherapy with or without anti-EGFR therapy for de novo metastatic nasopharyngeal carcinoma: a propensity score-matching study.

Comparison of induction chemotherapy combined with concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in Lymph-Node-Stage Nasopharyngeal Carcinoma based on propensity score-matching